Upwards arrow: Go back to top

Join us on LinkedIn for the latest news.

Building Next Generation Companies To Enhance Healthy Lifespan

Apollo Health Ventures is a transatlantic early stage Venture Capital firm actively co-founding and investing in transformative healthcare companies targeting age-related diseases and aging itself.

Biotechnology is the solution for a healthier lifespan and reduced healthcare spending.

By investing and thus enabling transformative healthcare companies in their scientific breakthroughs, we will impact human health within the next 10 years.

News & Press

News from our portfolio companies, recent advances in biotech, health tech and investments.

Booster Therapeutics launches with $15 M seed financingBooster Therapeutics launches with $15 M seed financing
10.10.2024
Booster Therapeutics launches with $15 M seed financing led by Apollo Health Ventures and Novo Holdings
HAYA Therapeutics Announces collaboartion with LillyHAYA Therapeutics Announces collaboartion with Lilly
4.9.2024
HAYA Therapeutics enters partnership with Eli Lilly worth up to $1 B to discover new genome targets for obesity and related metabolic conditions
GSK enters into a multi-year data licence agreement with Ochre BioGSK enters into a multi-year data licence agreement with Ochre Bio
17.7.2024
GSK enters into a multi-year data licence agreement with Ochre Bio
HAYA Therapeutics win Andreas & Thomas Struengmann AwardHAYA Therapeutics win Andreas & Thomas Struengmann Award
1.7.2024
HAYA Therapeutics Co-Founders Win Inaugural Andreas & Thomas Struengmann Award
Ochre Bio Announces Partnership With Boehringer IngelheimOchre Bio Announces Partnership With Boehringer Ingelheim
22.4.2024
Ochre Bio Signs $1 B Deal with Boehringer Ingelheim to Develop Liver Disease Drugs
Aeovian Pharmaceuticals Closes $50 Million Follow-On Round and  Moves Towards Human Clinical TrialsAeovian Pharmaceuticals Closes $50 Million Follow-On Round and  Moves Towards Human Clinical Trials
28.3.2024
Aeovian Pharmaceuticals Closes $50 Million Follow-On Round and Moves Towards Human Clinical Trials

Investment Strategy

We leverage potential by combining traditional funding with venture building, accomplishing a bigger and more diverse value creation in Europe and the US.

ACTIVE VENTURE CREATION

In our Venture Lab, we partner with scientific experts and turn untapped technologies into transformational companies. This way we acquire founder shares at nominal value– offering unique upsides to our investors.
Scientific & operational expertise
Building top teams
Access to capital & strong syndicates
Risk minimization by conducting killer experiments

Investing in best-in-class companies

Alongside of our venture lab approach, we generate additional value by identifying best-in-class companies at an early stage. Based on breakthrough science and led by amazing founders, we help those companies accelerate.
ACCESS
Access through extensive network and trust due to our deep knowledge
Successful track record since 2017
Accelerate
Leading players in follow on investment rounds
Support by talent and leadership recruitment, guidance on R&D as well as clinical trial and indication selection strategies.

Join us on LinkedIn for the latest news.